Health in Tajikistan 1,273 indicators covering health for Tajikistan. IndicatorLatest Year10-yr change Rank Prevalence of wasting, weight for height, male 6.9% 2023 down 30.3% 32nd Population with basic handwashing facilities at home 67.6% 2023 up 1.1% 54th Human Development Index 0.691 2023 up 5.5% 67th Prevalence of severe wasting, weight for height, female 1.1% 2023 down 71.8% 29th Prevalence of severe wasting, weight for height, male 2.1% 2023 down 51.2% 19th Prevalence of overweight, weight for height, female 5.2% 2023 down 18.8% 33rd Prevalence of overweight, weight for height, male 3.9% 2023 down 43.5% 52nd Prevalence of underweight, weight for age, female 4.7% 2023 down 63.8% 55th Prevalence of underweight, weight for age, male 5.6% 2023 down 58.5% 55th Prevalence of stunting, height for age, female 12.0% 2023 down 56.0% 60th Prevalence of stunting, height for age, male 15.1% 2023 down 42.8% 55th Tuberculosis - new and relapse cases 6,290 2011 up 79.3% 73rd Physiotherapists 130 2023 down 14.5% 87th Diarrhea treatment 61.7% 2017 up 27.5% 12th Pregnant women receiving prenatal care 91.8% 2017 up 3.4% 63rd New cases: pulmonary smear-negative 1,911 2012 — 56th Estimated number of pregnant women living with HIV needing 500 2025 unchanged 57th 3.3.1 (HIV Incidence) - New HIV infections per 1,000 uninfected 0.0229 2020 down 60.8% 75th Average death rate due to natural disasters 0.0838 2020 down 79.6% 95th Total number of notified TB cases 6,260 2014 up 22.2% 73rd The number of people with susceptibility test result for rifampicin 1,862 2021 — 50th Estimated number of pregnant women living with HIV 95 2025 up 75.9% 21st Mother-to-child HIV transmission rate 13 2024 down 65.2% 47th New cases: pulmonary smear unknown/not done 0 2012 — 109th Smear-positive tuberculosis treatment-success rate 80.0% 2011 up 11.1% 97th Share of one year olds who received the rotavirus vaccine 98 2024 up 15.3% 4th The number of people with susceptibility test result for rifampicin 100 2021 — 2nd Number of presumed malaria cases 0 2024 — 40th Number of indigenous malaria cases 0 2024 — 82nd Number of confirmed malaria cases 4 2024 down 20.0% 94th Total number of malaria cases 4 2024 down 20.0% 94th Retreatment cases: treatment after default 58 2012 down 83.1% 64th Number of indigenous P. falciparum malaria cases 0 2024 — 75th Number of suspected malaria cases 159,124 2020 down 15.5% 75th Retreatment cases: other 217 2012 down 62.6% 57th Retreatment cases: treatment after failure 146 2012 up 147.5% 40th Number of malaria positive cases by microscopy 0 2020 down 100.0% 94th Large household expenditures health 1.4 2018 down 4.1% 29th Share of population with large household expenditures on health 10pc 9.8 2018 up 51.7% 27th Number of malaria suspects examined by microscopy 159,124 2020 down 15.5% 52nd Absolute number of deaths from ambient particulate air pollution 4,000 2015 unchanged 89th Tuberculosis funding versus budget requirement 15.97 million 2025 up 429.4% 21st Antenatal care attendees who were positive for syphilis (%), reported 0.0% 2021 down 100.0% 92nd Percentage of people living with HIV who have suppressed viral loads 70 2025 up 191.7% 50th Percentage of people living with HIV receiving treatment who have 92 2025 up 41.5% 59th Height-for-age <-2 SD 13.7 2023 down 49.0% 61st Weight-for-age <-2 SD 5.2 2023 down 60.8% 59th Number of cases of cutaneous leishmaniasis reported 35 2021 up 169.2% 47th Proportion of the population with positive out-of-pocket household 30.8% 2019 up 28.7% 15th Number of cases of visceral leishmaniasis reported 14 2021 down 44.0% 32nd Exclusive breastfeeding 35.8% 2017 up 43.6% 54th Laboratories providing tuberculosis diagnostic services using culture 3 2014 — 75th Laboratories providing tuberculosis diagnostic services using sputum 1 2014 up 42.9% 81st Weight-for-height >+2 SD 4.6 2023 down 31.2% 43rd Vitamin A Supplementation, Semester 2 Coverage 99 2022 up 10.0% 1st Congenital syphilis number of cases, reported 1 2023 unchanged 57th Vitamin A Supplementation, Semester 1 Coverage 93 2022 down 5.1% 14th تغطية بجرعتين من فيتامين أ 93 2022 up 3.3% 10th Average cost of tuberculosis treatment multi drug resistant 257 2024 down 89.8% 90th Completeness of death registration with cause-of-death information 87.0% 2016 up 28.7% 68th ← Previous Page 20 of 22 Next →